Will FDA Advisors Back Expanded Indication for Vascepa Fish Oil?

<![CDATA[]]>(MedPage Today) — Whether the REDUCE-IT data are enough to give icosapent ethyl (Vascepa) an expanded indication will be on the table during a meeting Thursday of the FDA Endocrinologic and Metabolic Drugs Advisory Committee.
A supplemental New…

Source link

Related posts

New Guidelines to Expand Obesity Care


Study: Cell-Based Flu Vax Not Superior to Egg-Based Vax


Scientists find clue to 'maternal instinct'


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World